GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas

被引:61
作者
Davis, Drew G. [1 ]
Siddiqui, Momin T. [1 ]
Oprea-Ilies, Gabriela [1 ]
Stevens, Keith [1 ]
Osunkoya, Adeboye O. [1 ]
Cohen, Cynthia [1 ]
Li, Xiaoxian [1 ]
机构
[1] Emory Univ Hosp, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
关键词
Breast; GATA-3; FOXA1; Carcinoma; IHC; Urothelial; Prostatic; Mesothelioma; TMA; Unknown primary tumor; ESTROGEN-RECEPTOR; IMMUNOHISTOCHEMICAL EVALUATION; ANDROGEN RECEPTOR; CANCER; REVEALS; UTILITY; MARKER; A1;
D O I
10.1016/j.humpath.2015.09.015
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
GATA-3, a member of the GATA family of zinc-finger DNA binding proteins, and FOXA1, a member of the forkhead transcription factor family, are both associated with estrogen receptor expression. Both GATA-3 and FOXA1 are useful markers for breast carcinoma, but their expression in the different breast cancer subtypes and other neoplasms has not been thoroughly evaluated. We examined the expression of GATA-3 and FOXA1 in estrogen receptor positive, Her2/neu positive, and triple-negative breast carcinomas as well as in 10 other common carcinomas, including hepatocellular, colonic, pancreatic, gastric, endometrial (endometrioid), lung, prostatic, renal cell, urothelial, and ovarian serous carcinomas. Primary and metastatic melanomas and mesotheliomas were also evaluated. GATA-3 and FOXA1 staining of estrogen receptor positive breast carcinomas was seen in 96.6% and 96.2%, respectively. In triple-negative breast carcinomas, GATA-3 and FOXA1 staining was seen in 21.6% and 15.9%, respectively. Among the other tumors, GATA-3 staining was only seen in urothelial carcinoma (70.9%) and FOXA1 staining was only seen in prostatic (87.5%), urothelial (5.1%) carcinomas, and mesotheliomas (40.0%). In conclusion, GATA-3 and FOXA1 are excellent breast carcinoma markers; however, their utility is limited in the triple-negative subtype. The utility of FOXA.1 in diagnosing prostatic carcinoma and mesothelioma warrants further investigation. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:26 / 31
页数:6
相关论文
共 25 条
[1]   Expression of Forkhead- box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores [J].
Ademuyiwa, Foluso O. ;
Thorat, Mangesh A. ;
Jain, Rohit K. ;
Nakshatri, Harikrishna ;
Badve, Sunil .
MODERN PATHOLOGY, 2010, 23 (02) :270-275
[2]   Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours [J].
Albergaria, Andre ;
Paredes, Joana ;
Sousa, Barbara ;
Milanezi, Fernanda ;
Carneiro, Vitor ;
Bastos, Joana ;
Costa, Sandra ;
Vieira, Daniella ;
Lopes, Nair ;
Lam, Eric W. ;
Lunet, Nuno ;
Schmitt, Fernando .
BREAST CANCER RESEARCH, 2009, 11 (03)
[3]  
[Anonymous], BREAST CANC
[4]   Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation [J].
Asselin-Labat, Marie-Liesse ;
Sutherland, Kate D. ;
Barker, Holly ;
Thomas, Richard ;
Shackleton, Mark ;
Forrest, Natasha C. ;
Hartley, Lynne ;
Robb, Lorraine ;
Grosveld, Frank G. ;
van der Wees, Jacqueline ;
Lindeman, Geoffrey J. ;
Visvader, Jane E. .
NATURE CELL BIOLOGY, 2007, 9 (02) :201-U103
[5]   Forkhead transcription factors: Key players in development and metabolism [J].
Carlsson, P ;
Mahlapuu, M .
DEVELOPMENTAL BIOLOGY, 2002, 250 (01) :1-23
[6]   Estrogen receptor target gene: An evolving concept [J].
Carroll, Jason S. ;
Brown, Myles .
MOLECULAR ENDOCRINOLOGY, 2006, 20 (08) :1707-1714
[7]   Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1 [J].
Carroll, JS ;
Liu, XS ;
Brodsky, AS ;
Li, W ;
Meyer, CA ;
Szary, AJ ;
Eeckhoute, J ;
Shao, WL ;
Hestermann, EV ;
Geistlinger, TR ;
Fox, EA ;
Silver, PA ;
Brown, M .
CELL, 2005, 122 (01) :33-43
[8]   GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas [J].
Cimino-Mathews, Ashley ;
Subhawong, Andrea P. ;
Illei, Peter B. ;
Sharma, Rajni ;
Halushka, Marc K. ;
Vang, Russell ;
Fetting, John H. ;
Park, Ben Ho ;
Argani, Pedram .
HUMAN PATHOLOGY, 2013, 44 (07) :1341-1349
[9]   Semiquantitative GATA-3 Immunoreactivity in Breast, Bladder, Gynecologic Tract, and Other Cytokeratin 7-Positive Carcinomas [J].
Clark, Beth Z. ;
Beriwal, Surabhi ;
Dabbs, David J. ;
Bhargava, Rohit .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (01) :64-71
[10]   Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation [J].
DeGraff, David J. ;
Clark, Peter E. ;
Cates, Justin M. ;
Yamashita, Hironobu ;
Robinson, Victoria L. ;
Yu, Xiuping ;
Smolkin, Mark E. ;
Chang, Sam S. ;
Cookson, Michael S. ;
Herrick, Mary K. ;
Shariat, Shahrokh F. ;
Steinberg, Gary D. ;
Frierson, Henry F. ;
Wu, Xue-Ru ;
Theodorescu, Dan ;
Matusik, Robert J. .
PLOS ONE, 2012, 7 (05)